688192.SHG Dizal (Jiangsu) Pharmaceutical Co. Ltd. A
- Market cap
- CNY 29.8B
- P/E
- 8.0x
- P/B
- 24.35x
- ROE
- -37.2%
- Dividend yield
- 0.11%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688192.SHG undervalued?
Graham number688192.SHG trades 193.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A fundamental analysis
No fundamental analysis for Dizal (Jiangsu) Pharmaceutical Co. Ltd. A yet.
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dizal (Jiangsu) Pharmaceutical Co. Ltd. A
Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematolog…
Full company profileDizal (Jiangsu) Pharmaceutical Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 41.0M | 27.8M | 10.3M | 0.00 | 91.3M | 360M | 801M | 1.05B |
| Gross Profit | 5.19M | 3.46M | 1.28M | 0.00 | 88.1M | 351M | 767M | 1.00B |
| Operating Income | -450M | -760M | -665M | -786M | -1.12B | -933M | -760M | -420M |
| EBITDA | -427M | -731M | -613M | -673M | -1.03B | -851M | -667M | -392M |
| Net Income | -446M | -587M | -670M | -736M | -1.11B | -846M | -764M | -421M |
| EPS | -1.24 | -1.63 | -1.66 | -1.81 | -2.71 | -2.03 | -1.66 | -0.90 |
| Balance Sheet | ||||||||
| Total Assets | 627M | 1.22B | 2.75B | 2.08B | 1.50B | 1.72B | 3.00B | 2.85B |
| Total Liabilities | 177M | 136M | 283M | 323M | 648M | 1.52B | 1.71B | 1.72B |
| Shareholders' Equity | 450M | 1.08B | 2.46B | 1.76B | 849M | 194M | 1.29B | 1.13B |
| Cash & Short-term Investments | 207M | 509M | 364M | 122M | 74.2M | 250M | 291M | 179M |
| Cash Flow | ||||||||
| Operating Cash Flow | -366M | -410M | -492M | -603M | -968M | -651M | -588M | - |
| Capital Expenditure | 13.8M | 212M | 8.98M | 73.8M | 32.1M | 138M | 170M | 94.6M |
| Free Cash Flow | -379M | -622M | -501M | -677M | -1.00B | -788M | -759M | -643M |
| Ratios | ||||||||
| ROE | -99.0% | -54.4% | -27.2% | -41.9% | -130.5% | -436.6% | -59.1% | -37.2% |
| ROA | -71.1% | -48.3% | -24.4% | -35.4% | -74.0% | -49.2% | -25.4% | -14.8% |
| Net Profit Margin | -1,086.7% | -2,113.1% | -6,512.9% | - | -1,213.4% | -235.1% | -95.4% | -40.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A dividends
- Dividend yield
- 0.11%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 32.9M | 0.07 | - |
| 2024 | CNY 20.6M | 0.05 | - |
| 2023 | CNY 3.38M | 0.01 | - |
| 2022 | - | - | - |
| 2021 | CNY 52.2K | 0.00 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Dizal (Jiangsu) Pharmaceutical Co. Ltd. A
- Insiders 40.68%
- Institutions 35.67%
- Public & others 23.65%
- Shares outstanding 465M
- Free float 169M
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A company profile
- Company name
- Dizal (Jiangsu) Pharmaceutical Co. Ltd. A
- Ticker
- 688192.SHG
- ISIN
- CNE1000055W8
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,009
- Fiscal year end
- December
- Address
- No. 199 and 245 Liangjing Rd, Shanghai, China, 201203
- Phone
- 86 21 6109 7800
- Website
- dizalpharma.com
About Dizal (Jiangsu) Pharmaceutical Co. Ltd. A
Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. Dizal (Jiangsu) Pharmaceutical Co., Ltd. was founded in 2017 and is based in Shanghai, China.
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A management
10- Dr. Zhang Xiaolin Ph.D.GM & Chairman · born 1964
- Mr. Lyu Hongbin M.B.A.Chief Financial Officer · born 1978
- Ms. Zhiwei ZhangDeputy GM, VP & Head of Operations · born 1982
- Dr. Qingbei Zeng Ph.D.Deputy GM, Chief Scientist & Senior VP · born 1962
- Dr. Zhenfan Yang M.D., Ph.D.Deputy GM & Chief Medical Officer · born 1968
- Ms. Qingyi WuDeputy GM & Chief Commercial Officer · born 1974
- Dr. Honchung TsuiDeputy GM, Senior VP & Head of Medicinal Chemistry Department · born 1968
- Dr. Shih-Ying Chang Ph.D.Deputy GM, VP and Head of Chemistry, Production & Control Department · born 1963
- Ms. Suqin ChenDeputy GM & Senior VP of Clinical Operations · born 1967
- Mr. Weijun QiaoVP & Head of Registration Affairs · born 1966